Scpharmaceuticals Valuation
| SCPH Stock | USD 3.28 0.14 4.09% |
At this time, the company appears to be overvalued. Scpharmaceuticals has a current Real Value of $2.76 per share. The regular price of the company is $3.28. Our model measures the value of Scpharmaceuticals from inspecting the company fundamentals such as Return On Equity of -1.67, operating margin of (1.81) %, and Shares Outstanding of 50.04 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Scpharmaceuticals' valuation include:
Price Book 5.5729 | Enterprise Value | Enterprise Value Ebitda (6.69) | Price Sales 5.4208 | Enterprise Value Revenue 4.3646 |
Overvalued
Today
Please note that Scpharmaceuticals' price fluctuation is risky at this time. Calculation of the real value of Scpharmaceuticals is based on 3 months time horizon. Increasing Scpharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Scpharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Scpharmaceuticals Stock. However, Scpharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.28 | Real 2.76 | Target 17.5 | Hype 3.28 |
The intrinsic value of Scpharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Scpharmaceuticals' stock price.
Estimating the potential upside or downside of Scpharmaceuticals helps investors to forecast how Scpharmaceuticals stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Scpharmaceuticals more accurately as focusing exclusively on Scpharmaceuticals' fundamentals will not take into account other important factors: When choosing an evaluation method for Scpharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Scpharmaceuticals Cash |
|
Scpharmaceuticals Valuation Trend
Scpharmaceuticals' real value analysis enables investors to forecast the earnings more efficiently. Using both Scpharmaceuticals' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Scpharmaceuticals Total Value Analysis
Scpharmaceuticals is at this time projected to have valuation of 132.15 M with market capitalization of 164.13 M, debt of 40.27 M, and cash on hands of 55.85 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Scpharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
132.15 M | 164.13 M | 40.27 M | 55.85 M |
Scpharmaceuticals Investor Information
About 82.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.95. Scpharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Scpharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Scpharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Scpharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Scpharmaceuticals has an asset utilization ratio of 14.39 percent. This signifies that the Company is making $0.14 for each dollar of assets. An increasing asset utilization means that Scpharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Scpharmaceuticals Ownership Allocation
Scpharmaceuticals shows a total of 50.04 Million outstanding shares. The majority of Scpharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Scpharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Scpharmaceuticals. Please pay attention to any change in the institutional holdings of Scpharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Scpharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 13.59 M. Net Loss for the year was (54.81 M) with profit before overhead, payroll, taxes, and interest of 21.11 M.About Scpharmaceuticals Valuation
An absolute valuation paradigm, as applied to Scpharmaceuticals Stock, attempts to find the value of Scpharmaceuticals based on its fundamental and basic technical indicators. By analyzing Scpharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Scpharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Scpharmaceuticals. We calculate exposure to Scpharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Scpharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 11.2 M | 11.8 M | |
| Pretax Profit Margin | (3.63) | (3.81) | |
| Operating Profit Margin | (3.67) | (3.85) | |
| Net Loss | (3.63) | (3.81) | |
| Gross Profit Margin | 0.65 | 0.58 |
Scpharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 38.5 M |
Scpharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Scpharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Scpharmaceuticals we look at many different elements of the entity such as Scpharmaceuticals's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Scpharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Scpharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Scpharmaceuticals' worth.Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |